Skip to main content

Table 2 Characteristics of the 14 randomized controlled trials Included in the meta-analysis

From: Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials

Study or author

Baseline LDL-C Level, (mg/dl)

Change in LDL-Ca(mg/dl)

Baseline HDL-C Level,(mg/dl)

Change in HDL-Ca,(mg/dl)

Baseline Triglyceride

Level, (mg/dl)

Change in Triglyceridea,(mg/dl)

CARDS 2009 [9]

—

—

—

—

—

—

Masanori 2011 [10]

137

−54

49

+4

162

−32

Dalla 2003 [11]

149

−41

55

+1

162

−32

Linda 2001 [12]

125.5

−28.3

50.9

+2.2

76

−9.5

E. Hommel 1992 [13]

162.54

−61.92

57.7

+1.55

120.5

+11.52

Lam 1995 [14]

166.4

−50.31

42.57

−0.39

194.92

−17.72

S.Nielsen 1993 [15]

170.28

−58.05

48.76

−0.39

204.7

−20.4

Zhang 1995 [16]

123

−23

62

+1

105

−12

Giancarlo 1997 [17]

181.89

−54.18

50.31

0

141.8

−26.6

Tsukasa 2005 [18]

—

—

—

—

—

—

Tsukasa 2001 [19]

208

−62

22

+16

202

−42

Wu 2013 [20]

171.05

−61.15

—

—

225.9

−65.6

Du 2015 [21]

—

—

—

—

—

—

Xiang 2005 [22]

166.41

−19.35

54.18

+7.74

221.5

−17.72

  1. aIn statin group;—:not report